Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Sai-Hong Ignatius OuChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CAAbstract: Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-11-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/crizotinib-a-novel-and-first-in-class-multitargeted-tyrosine-kinase-in-a8720 |